|
Pulmonary Fibrosis
|
0.560 |
Biomarker
|
disease |
BEFREE |
OCA administration, even after the establishment of PF, significantly improved pulmonary function, normalizing PAO, and reverted the bleomycin-induced lung alterations, with significant reduction of markers of inflammation (CD206, COX2, HIF1, IL1β, MCP1), epithelial proliferation (CTGF, PDGFa) and fibrosis (COL1A1, COL3A1, ET1, FN1, MMPs, αSMA, SNAIs, TGFβ1, TIMPs).
|
29923060 |
2019 |
|
Pulmonary Fibrosis
|
0.560 |
AlteredExpression
|
disease |
BEFREE |
These results demonstrate that FBP may prevent bleomycin-induced PF development through reduced expression of collagen and other ECM components mediated by a reduced TIMP-1 and MMP2 expression.
|
31509566 |
2019 |
|
Pulmonary Fibrosis
|
0.560 |
Biomarker
|
disease |
BEFREE |
IL-33 can regulate deposition of ECM and promote the process of pulmonary fibrosis by inducing the imbalance between MMP-9 and TIMP-1.
|
29417309 |
2018 |
|
Pulmonary Fibrosis
|
0.560 |
Biomarker
|
disease |
BEFREE |
TIMP1 promotes multi-walled carbon nanotube-induced lung fibrosis by stimulating fibroblast activation and proliferation.
|
27852133 |
2017 |
|
Pulmonary Fibrosis
|
0.560 |
AlteredExpression
|
disease |
BEFREE |
Intranasal administration of curcumin significantly inhibited airway inflammation and pulmonary fibrosis, where MMP-9 activities were decreased along with α-smooth muscle actin (α-SMA), MMP-9, TIMP-1, and eotaxin expressions.
|
27866296 |
2017 |
|
Pulmonary Fibrosis
|
0.560 |
Biomarker
|
disease |
BEFREE |
MMP-2, MMP-9, and TIMP-1 accumulation were quantified to evaluate the lung fibrosis exposure to PQ.
|
26129822 |
2016 |
|
Pulmonary Fibrosis
|
0.560 |
Therapeutic
|
disease |
RGD |
Inhibitory effects of alkaline extract of Citrus reticulata on pulmonary fibrosis.
|
23318412 |
2013 |
|
Pulmonary Fibrosis
|
0.560 |
Biomarker
|
disease |
CTD_human |
In conclusion, unbalanced MMP/TIMP-1 expression and excessive gelatinolytic activity contribute to PQ-induced pulmonary fibrosis.
|
21468558 |
2011 |
|
Hypertensive disease
|
0.540 |
Biomarker
|
group |
BEFREE |
MMP-9 and TIMP-1 in placenta of hypertensive disorder complicating pregnancy.
|
31258700 |
2019 |
|
Hypertensive disease
|
0.540 |
Biomarker
|
group |
BEFREE |
Curcumin modulates covalent histone modification and TIMP1 gene activation to protect against vascular injury in a hypertension rat model.
|
29285138 |
2017 |
|
Hypertensive disease
|
0.540 |
GeneticVariation
|
group |
BEFREE |
The presence of type 2 diabetes associated with 3.2-fold increased PAI-1 expression (adjusted p=0.033), while the presence of hypertension associated with about 50% reduction of IL-8 and TIMP-1.
|
25496999 |
2015 |
|
Hypertensive disease
|
0.540 |
Biomarker
|
group |
CTD_human |
Fosinopril and valsartan intervention in gene expression of Klotho, MMP-9, TIMP-1, and PAI-1 in the kidney of spontaneously hypertensive rats.
|
21051829 |
2010 |
|
Hypertensive disease
|
0.540 |
Biomarker
|
group |
RGD |
Upregulation of tissue inhibitor of metalloproteases-1 (TIMP-1) and procollagen-N-peptidase in hypertension-induced renal damage.
|
17977875 |
2008 |
|
Hypertensive disease
|
0.540 |
AlteredExpression
|
group |
LHGDN |
Circulating pretreatment MMP-9 and TIMP-1 levels were significantly higher in patients with hypertension than in the normotensive controls (P =.0041 and P =.0166, respectively).
|
15363817 |
2004 |
|
Heart Diseases
|
0.510 |
Biomarker
|
group |
BEFREE |
In non-COPD, male sex, age, burden of smoking, heart disease and MMP-9/TIMP-1 ratio were associated with increased risk for death, while increased TIMP-1 was protective.
|
29650051 |
2018 |
|
Heart Diseases
|
0.510 |
Biomarker
|
group |
CTD_human |
Genomic biomarkers for cardiotoxicity in rats as a sensitive tool in preclinical studies.
|
23558518 |
2013 |
|
Heart Diseases
|
0.510 |
Biomarker
|
group |
RGD |
[The effect of bone marrow mesenchymal stem cell transplantation on diabetic cardiomyopathy].
|
19134282 |
2008 |
|
Liver Cirrhosis, Experimental
|
0.500 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
|
Diabetes Mellitus, Experimental
|
0.500 |
Biomarker
|
disease |
CTD_human |
Altered matrix metalloproteinases and tissue inhibitors of metalloproteinases in embryos from diabetic rats during early organogenesis.
|
21963884 |
2011 |
|
Liver Cirrhosis, Experimental
|
0.500 |
Biomarker
|
disease |
CTD_human |
Heme oxygenase-1 regulates the major route involved in formation of immune hepatic fibrosis in rats.
|
21163135 |
2010 |
|
Vascular Diseases
|
0.500 |
Biomarker
|
group |
CTD_human |
Investigation of the molecular mechanisms preceding PDE4 inhibitor-induced vasculopathy in rats: tissue inhibitor of metalloproteinase 1, a potential predictive biomarker.
|
17569694 |
2007 |
|
Vascular Diseases
|
0.500 |
Biomarker
|
group |
RGD |
Investigation of the molecular mechanisms preceding PDE4 inhibitor-induced vasculopathy in rats: tissue inhibitor of metalloproteinase 1, a potential predictive biomarker.
|
17569694 |
2007 |
|
Diabetes Mellitus, Experimental
|
0.500 |
Biomarker
|
disease |
RGD |
[Modulative effect of zhenqing recipe on expressions of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in experimental type 2 diabetic rats].
|
17569353 |
2006 |
|
Liver Cirrhosis, Experimental
|
0.500 |
Biomarker
|
disease |
CTD_human |
Cytokine blockade inhibits hepatic tissue inhibitor of metalloproteinase-1 expression and up-regulates matrix metalloproteinase-9 in toxic liver injury.
|
16762003 |
2006 |
|
Liver Cirrhosis, Experimental
|
0.500 |
Biomarker
|
disease |
CTD_human |
Correlation between TIMP-1 expression and liver fibrosis in two rat liver fibrosis models.
|
16718785 |
2006 |